Innovating Women’s Reproductive Health Therapeutics

For too long, women have been overlooked and undervalued. So it’s no surprise that women’s reproductive health has suffered a similar fate. The consequence runs deep, causing pain that isn’t just physical, but emotional, mental, and financial, too. After all, in many cases this sits right at the heart of one of our most basic drives in life: to secure our future.

Answering this critical unmet need takes extraordinary minds. Welcome to ObsEva. Born in Switzerland in 2012, we’re a clinical-stage biopharmaceutical company with the skills, experience, and backing to usher in a new era in women’s reproductive health.

Our purpose is simple, bring to market the products women need. We think of ourselves as the people who nurture your health when nature loses its way.

ObsEva. Nature meets Nurture

Click Here to view Job Vacancies/Talent Community

Learn more Company Corporate Presentation

Clinical Studies

We are currently conducting three international clinical research studies.

Read more

Our Pipeline

Yselty UF

(OBE2109)
Oral GnRH
receptor antagonist

Milestones

Uterine Fibroids

  • MAA: filed Nov2020
  • NDA: Q3:21
  • PRIMROSE 1:
  • Positive 24W primary endpoint results (July2020)
  • Sustained efficacy and continued safety confirmed at 52W (Dec2020)
  • 76W (6 months post treatment) results expected Q2:21
  • PRIMROSE 2:
  • Positive 24W primary endpoint results (Dec2019)
  • Sustained efficacy and continued safety confirmed at 52W (Jul2020)
  • Continued pain reduction and evidence of bone mineral density (BMD) recovery at 76W (6 months post treatment) (Dec2020)

Commercial rights

  • Exclusive Worldwide (ex-Asia)
Learn more

Yselty EM

(OBE2109)
Oral GnRH
receptor antagonist

Milestones

Endometriosis

  • Phase 3 Edelweiss 3 trial read-out (24W) Q42021
  • Phase 3 Edelweiss 2 trial discontinued Jan2021
  • Enrollment of new patients placed on voluntary hold Q1:20 amid COVID-19 pandemic
  • Initiated Phase 3 in Q2:19
  • Positive Phase 2b results in 2018/19

Commercial rights

  • Exclusive Worldwide (ex-Asia)
Learn more

Ebopiprant

(OBE022)
Oral and selective
prostaglandin F2 alpha
receptor antagonist

Milestones

  • Positive Phase 2 Proof-of-Concept for the Treatment of Preterm Labor Nov2020
  • Phase 2b dose range finding initiation Q4:2021

Commercial rights

  • Exclusive Worldwide
Learn more

Nolasiban

(OBE001)
Oral oxytocin
receptor antagonist

Milestones

  • In development, partnership with Yuyuan BioScience Technology (PRC)

Commercial rights

  • Exclusive Worldwide (ex China)
  • Partnership with Yuyuan BioScience Technology (PRC)
Learn more

ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021

June 10, 2021

-PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation– – Phase 2b/3 adaptive…

Learn more

ObsEva in the media

Learn more

Other ObsEva press releases

Learn more
 

Work With Us

Are you ready to join an innovative biopharmaceutical company that’s advancing women’s reproductive health and pregnancy therapeutics?
Check out our vacancies and/or register to our talent community by clicking on the link below.

Vacancies/Talent Community

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue